Q32 Bio (Q32 Bio) Cash-to-Debt : 6.72 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Q32 Bio's cash to debt ratio for the quarter that ended in Mar. 2024 was 6.72.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Q32 Bio could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Q32 Bio's Cash-to-Debt or its related term are showing as below:

QTTB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5 Med: 0.98 Max: 6.72
Current: 6.72

During the past 3 years, Q32 Bio's highest Cash to Debt Ratio was 6.72. The lowest was 0.50. And the median was 0.98.

QTTB's Cash-to-Debt is ranked worse than
50.3% of 1489 companies
in the Biotechnology industry
Industry Median: 6.91 vs QTTB: 6.72

Q32 Bio Cash-to-Debt Historical Data

The historical data trend for Q32 Bio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Q32 Bio Cash-to-Debt Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

6.49

0.98

0.50

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial			0.98	N/A	0.73	0.50	6.72

Competitive Comparison of Q32 Bio's Cash-to-Debt

For the Biotechnology subindustry, Q32 Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Cash-to-Debt falls into.

Q32 Bio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Q32 Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	25.617	/	(1.416	+	49.424)
	=	0.50

Q32 Bio's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	135.312	/	(4.648	+	15.499)
	=	6.72

Q32 Bio (NAS:QTTB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Q32 Bio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024